Clinical trial
A Phase I Trial of CD19-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells Genetically Engineered to Secrete Interleukin 12 (IL-12) and With a Truncated Human Epidermal Growth Factor Receptor (EGFRt) in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies
NCT06343376 is registered in ClinicalTrials.gov with Roswell Park Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Trial of CD19-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells Genetically Engineered to Secrete Interleukin 12 (IL-12) and With a Truncated Human Epidermal Growth Factor Receptor (EGFRt) in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies
- Lead sponsor
- Roswell Park Cancer Institute
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- November 26, 2024
- Completion date
- January 3, 2025
- Enrollment
- 1 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
recurrent chronic lymphocytic leukemia, recurrent diffuse large b-cell lymphoma, recurrent follicular lymphoma, recurrent high grade b-cell lymphoma, recurrent mantle cell lymphoma, recurrent transformed chronic lymphocytic leukemia, recurrent transformed follicular lymphoma to diffuse large b-cell lymphoma, refractory chronic lymphocytic leukemia, refractory diffuse large b-cell lymphoma, refractory follicular lymphoma, refractory high grade b-cell lymphoma, refractory mantle cell lymphoma, refractory transformed chronic lymphocytic leukemia, refractory transformed follicular lymphoma to diffuse large b-cell lymphoma